ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 793,400 shares, a decrease of 52.2% from the February 28th total of 1,660,000 shares. Based on an average daily volume of 9,120,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company’s shares are short sold.

ProPhase Labs Trading Down 4.3 %

Shares of ProPhase Labs stock traded down $0.02 during midday trading on Friday, reaching $0.44. 3,276,359 shares of the company’s stock traded hands, compared to its average volume of 2,472,609. The stock has a 50 day moving average of $0.41 and a 200-day moving average of $1.08. ProPhase Labs has a 12 month low of $0.22 and a 12 month high of $7.48. The company has a market cap of $10.50 million, a PE ratio of -0.35 and a beta of -0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47.

Hedge Funds Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC boosted its position in ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of ProPhase Labs in the 4th quarter valued at approximately $36,000. Sheets Smith Wealth Management bought a new stake in shares of ProPhase Labs during the fourth quarter valued at approximately $158,000. Geode Capital Management LLC grew its stake in ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after purchasing an additional 13,590 shares during the period. Finally, Squarepoint Ops LLC bought a new position in ProPhase Labs in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 9.45% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating for the company.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.